Characterization of the Interaction Between Secreted Frizzled-Related Protein 2 (SFRP2) and Frizzled-5 (FZD5) by Co-Immunoprecipitation

School Name

Governor's School for Science & Mathematics

Grade Level

12th Grade

Presentation Topic

Physiology and Health

Presentation Type

Mentored

Mentor

Mentor: Nancy DeMore, Medical University of South Carolina

Abstract

Cancer is the second most common cause of death in the United States and affects approximately 39.6 percent of men and women. Angiogenesis, the creation of blood vessels, is a key element in the growth of cancerous tumors since blood vessels supply the nutrients and oxygen that tumors need to grow. Current forms of therapy that target angiogenesis are not always effective at eliminating tumors, so new forms of treatment that affect angiogenesis must be developed. Secreted Frizzled-Related Protein 2 (SFRP2) and Frizzled-5 (FZD5) are two proteins that show promise as cancer treatments. Both SFRP2 and FZD5 are associated with angiogenesis, cancer growth, and the Wnt signaling pathway, which controls cellular processes such as cell migration and the development of organs in embryos. Verifying that a relationship exists between the two proteins would clarify how they work together to promote tumor growth. We performed a co-immunoprecipitation to determine whether FZD5 binds to SFRP2 by isolating SFRP2 with FZD5 bound to it from a 2H11 cell lysate using magnetic beads coated with anti-SFRP2 antibody. A series of Western blots confirmed that SFRP2 and FZD5 are expressed in the cell lysate and that FZD5 binds to SFRP2, which shows that FZD5 is the receptor of SFRP2. Eventually, therapies that target this interaction could inhibit angiogenesis and the related tumor growth.

Location

Wall 318

Start Date

3-25-2017 2:00 PM

Presentation Format

Oral and Written

Group Project

No

COinS
 
Mar 25th, 2:00 PM

Characterization of the Interaction Between Secreted Frizzled-Related Protein 2 (SFRP2) and Frizzled-5 (FZD5) by Co-Immunoprecipitation

Wall 318

Cancer is the second most common cause of death in the United States and affects approximately 39.6 percent of men and women. Angiogenesis, the creation of blood vessels, is a key element in the growth of cancerous tumors since blood vessels supply the nutrients and oxygen that tumors need to grow. Current forms of therapy that target angiogenesis are not always effective at eliminating tumors, so new forms of treatment that affect angiogenesis must be developed. Secreted Frizzled-Related Protein 2 (SFRP2) and Frizzled-5 (FZD5) are two proteins that show promise as cancer treatments. Both SFRP2 and FZD5 are associated with angiogenesis, cancer growth, and the Wnt signaling pathway, which controls cellular processes such as cell migration and the development of organs in embryos. Verifying that a relationship exists between the two proteins would clarify how they work together to promote tumor growth. We performed a co-immunoprecipitation to determine whether FZD5 binds to SFRP2 by isolating SFRP2 with FZD5 bound to it from a 2H11 cell lysate using magnetic beads coated with anti-SFRP2 antibody. A series of Western blots confirmed that SFRP2 and FZD5 are expressed in the cell lysate and that FZD5 binds to SFRP2, which shows that FZD5 is the receptor of SFRP2. Eventually, therapies that target this interaction could inhibit angiogenesis and the related tumor growth.